HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American Dream's Nightmare Ends, But It Doubts NAD Standard For Claims

This article was originally published in The Rose Sheet

Executive Summary

Dietary supplement multi-level marketer American Dream says it will comply with NAD's recommendations even though "it disagrees with the standard NAD applied to its claims for its dietary supplement."

You may also be interested in...

NAD Could Jog Cognitive Benefit Supplement Firm's Memory With FTC Call

NAD refers UltraMax Health's supplement claim to the FTC after it fails to provide substantiation. CRN emphasizes claims alone are not the problem, but the firm's failure to provide substantiation.

FTC Leaves Supplement Industry Still Waiting For Shift Away From RCT Standard For Claims

FTC's "standard is the same. There's not any per se lower standard for substantiation just because you position your product as a supplement," says agency attorney Michelle Rusk. Supplement industry stakeholders, though, argue that FTC has no basis to require RCTs for structure/function claims.

PhytoZon Claims Could Land American Dream In Regulatory Nightmare

NAD refers questions about PhytoZon claims to FDA and FTC after American Dream declines to submit evidence in a challenge by the Council for Responsible Nutrition. The multi-level marketer refers NAD attorneys to its website with links to around 500 studies, which look at ingredients and not the product.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts